IGF2 and prostate cancer: Loss of imprinting leads to over expression of IGF-2 and has been demonstrated in multiple tumors including solitary fibrous tumors (independent of anatomical location), Wilm’s tumors, metastatic hemangiopericytomas, mesotheliomas, hepatocellular carcinomas, gastrointestinal stromal tumors (GIST), colorectal adenomas, osteosarcomas, rhabdomyosarcomas, leiomyosarcomas, paragangliomas, prostate cancers, breast cancers and bladder cancers [2,15].